TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma
- Supplementary File 1:
ZIP-Document (ZIP, 1898 KiB)
Tabouret, E.; Wang, H.; Amin, N.; Jung, J.; Appay, R.; Cui, J.; Song, Q.; Cardone, A.; Park, D.M.; Gilbert, M.R.; Pant, H.; Zhuang, Z. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935. https://doi.org/10.3390/cancers12071935
Tabouret E, Wang H, Amin N, Jung J, Appay R, Cui J, Song Q, Cardone A, Park DM, Gilbert MR, Pant H, Zhuang Z. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers. 2020; 12(7):1935. https://doi.org/10.3390/cancers12071935
Chicago/Turabian StyleTabouret, Emeline; Wang, Herui; Amin, Niranjana; Jung, Jinkyu; Appay, Romain; Cui, Jing; Song, Qi; Cardone, Antonio; Park, Deric M.; Gilbert, Mark R.; Pant, Harish; Zhuang, Zhengping. 2020. "TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma" Cancers 12, no. 7: 1935. https://doi.org/10.3390/cancers12071935